SCHEMBL25817126

SCHEMBL25817126

Cc1cc(C=O)c(OCc2ccccc2)c(C)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.45
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
CCNB2 O95067 1/20 0.44
CDK1 P06493 1/20 0.44
CDK4 P11802 1/20 0.44
CCNB1 P14635 1/20 0.44
CCND1 P24385 1/20 0.44
CCNB3 Q8WWL7 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
PTGER4 P35408 2/20 0.43
PTGER3 P43115 2/20 0.43
PTGER2 P43116 2/20 0.43
LMNA P02545 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
PTGER1 P34995 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25877526 0.88 PTPN1 (0.48) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL25877949 0.85 PTPN1 (0.45) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL25877759 0.84 PTPN1 (0.45) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL25877469 0.84 PTPN1 (0.45) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL25877765 0.84 PTPN1 (0.51) PTPN1MAOAMAOBTDP1L3MBTL1
SCHEMBL25877764 0.83 PTPN1 (0.41) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL20607402 0.82 POLB (0.43) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL20607246 0.82 LMNA (0.46) PTPN1MAOAMAOBTDP1L3MBTL1
SCHEMBL2574855 0.81 PTGER4 (0.55) PTPN1MAOAMAOBCCNB2CDK1
SCHEMBL22067805 0.81 ERN1 (0.50) PTPN1MAOAMAOBTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 US disclosed
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 PTPN1 1336/4885MAOA 1354/4885MAOB 1384/4885
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 PTPN1 1336/4885MAOA 1354/4885MAOB 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.